The EZH2 small-molecule inhibitor is being evaluated in clinical trials for the treatment of cancers, including tazemetostat [21], thus we further evaluated the relevance of DMDRMR/miR-378a-5p axis in the efficacy of tazemetostat. Here, EZH2 is linked to cancer.